Login to Your Account



Repurposing CAR T cells

CAR T-cell therapy goes back to its HIV roots

By Anette Breindl
Senior Science Editor

Monday, October 16, 2017

Chimeric antigen receptor (CAR) T cells crossed the finish line as a cancer therapy, when the FDA approved Kymriah (tisagenlecleucel, formerly CTL-019, Novartis AG), in August. But they had first entered the drug development race in another indication – more than 20 years ago.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription